![Steven M. Toler](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profiel
Steven M.
Toler served as Vice President-Pharmaceutical Development at Bellicum Pharmaceuticals, Inc. from 2015 to 2018 and as Vice President-Clinical Pharmaceutical Sciences at Targacept, Inc. from 2013 to 2015.
He holds a doctorate degree from Mercer University and Chandler Medical Center, and an undergraduate degree from Georgia State University.
Eerdere bekende functies van Steven M. Toler
| Bedrijven | Functie | Einde |
|---|---|---|
| BELLICUM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-05-2018 |
Targacept, Inc.
 Targacept, Inc. Pharmaceuticals: OtherHealth Technology Discovers and develops nicotinic acetylcholine receptor based therapies | Corporate Officer/Principal | 31-03-2015 |
Opleiding van Steven M. Toler
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
33
Eerstegraads connecties
5
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
Bellicum Pharmaceuticals, Inc.
 Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops novel cellular immunotherapies for various forms of cancer | Health Technology |
Mercer University
 Mercer University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Discovers and develops nicotinic acetylcholine receptor based therapies | Health Technology |
Georgia State University
 Georgia State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Chandler Medical Center
 Chandler Medical Center Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
